Provided by Tiger Trade Technology Pte. Ltd.

Vanguard Health Care ETF

315.06
+2.180.70%
Volume:351.28K
Turnover:111.21M
Market Cap:18.96B
PE:34.20
High:318.31
Open:313.41
Low:313.41
Close:312.88
52wk High:330.75
52wk Low:263.00
Shares:60.18M
Float Shares:60.18M
Volume Ratio:1.81
T/O Rate:0.58%
Dividend:4.63
Dividend Rate:1.47%
EPS(TTM):9.21
EPS(LYR):41.51
ROE:3.75%
ROA:0.89%
PB:0.96
PE(LYR):7.59

Loading ...

Sector Update: Healthcare

MT Newswires Live
·
2 hours ago

Exchange-Traded Funds Lower as US Equities Decline After Midday

MT Newswires Live
·
2 hours ago

Moderna, Merck Climb on Collaboration with Tempus

Reuters
·
3 hours ago

Merck's Keytruda is Dealt a Legal Setback. It's Good News for This Biotech Stock.

Dow Jones
·
3 hours ago

Eli Lilly and Co Stock (LLY) Moved Up by 3.94% on Oct 7: Facts Behind the Movement

TradingKey
·
3 hours ago

Amgen Inc Stock (AMGN) Moved Up by 3.06% on Oct 7: A Full Analysis

TradingKey
·
3 hours ago

S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT

Reuters
·
3 hours ago

Pharma Lobby Sues Trump Administration over Medicare Drug Price Cuts

Reuters
·
Yesterday

Eli Lilly is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Yesterday

What Eli Lilly Stock's First Line Jaypirca Approval Means For Shareholders

Simply Wall St.
·
Yesterday

Halozyme Therapeutics Shares up 2% After Court Win Against Merck to Block Subcutaneous Keytruda in Select Markets

THOMSON REUTERS
·
Yesterday

Micro-Cap Stock Veraxa Biotech is Down 96% This Year. Can Next-Gen Drug Testing Save It?

Dow Jones
·
Yesterday

Morgan Stanley Adjusts Price Target on Merck to $177 From $179

MT Newswires Live
·
Yesterday

AbbVie’s telisotuzumab adizutecan gets two FDA Breakthrough Therapy Designations

TIPRANKS
·
Yesterday

Tempus AI announces multi-year collaboration with Moderna, Merck

TIPRANKS
·
Yesterday

Halozyme announces Dutch court of the Hague found Merck infringed patents

TIPRANKS
·
Yesterday

AbbVie Says FDA Grants Breakthrough Therapy Status for ABBV-400 in Metastatic Colorectal Cancer

Reuters
·
Yesterday

Tempus Expands Multi-Year Collaboration with Moderna, Merck on V940 Melanoma Vaccine Commercialization Support

Reuters
·
Yesterday

Abbvie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations from the U.S. FDA for Crc and Nsclc

THOMSON REUTERS
·
Yesterday

Halozyme Therapeutics - Iv Version of Keytruda Remains Available and not Covered by Halozyme's Patent or Court Injunction

THOMSON REUTERS
·
Yesterday